Nucleic Acids Research, 1994, Vol. 22, No. 6 1012-1017
© 1994
MOLECULAR BIOLOGY |
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53
Istituto di Ricerche Farmacologiche ‘Mario Negri’ via Eritrea, 62, 20157 Milan, Italy
*To whom correspondence should be addressed
Received December 20, 1993. Revised February 3, 1994. Accepted February 3, 1994.
Utilizing a temperature sensitive p53 mutant (pLTRp53cGval135) which expresses mutant p53 at 37°C and a wild-type like p53 at 32°C, we transfected a human ovarian cancer cell line (SKOV3) which does not express endogenous p53. Among the different clones obtained, we selected three clones. Two were obtained from simultaneous transfectlon of p53 and neomycin resistance expression plasmids (SK23a and SK9), the other was obtained from transfection experiments utilizing the neomycin resistance gene only (SKN). Introduction of mutant p53 did not alter the morphology or growth characteristics of this ovarian cancer cell line. Upon shifting to the permissive temperature, a dramatic change in morphology and growth rate was observed in SK23a and SK9 cells that is associated with the presence of a wild-type like p53. SKN and SKOV3 cells maintained at 32°C did not change morphology and only slightly reduced proliferation. Both SK23a and SK9 cells did not show evidence of apoptosis when measured up to 72 hours of maintenance at 32°C. In contrast to what observed in other cell lines, SK23a and SK9 cells maintained at 32°C were not blocked in G1, but they were accumulated in G2-M. This accumulation was transient and could be due either to a blockade or to a delay in the G2 progression. No down-regulation of c-myc was observed in p53 expressing clones when shifted to the permissive temperature. In these conditions gadd45 mRNA expression was highly stimulated in SK9 and SK23a cells but not In SKN cells. In both clones Gas1 mRNA was not detected either at 37°C or 32°C. This system represents a new and useful model for studying the effect of the absence of p53 (SKOV3 or SKN), presence of mutated p53 (SK23a and SK9 kept at 37°C) or wild type p53 (SK23a and SK9 kept at 32°C) on the mechanism of response of cancer cells to DNA damaging agents.
+On leave from Institute of Cytology. Academy of Science. St Petersburg. Russia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. P. Adams, C. C. Shaller, E. Dadachova, H. H. Simmons, E. M. Horak, A. Tesfaye, A. J. P. Klein-Szanto, J. D. Marks, M. W. Brechbiel, and L. M. Weiner A Single Treatment of Yttrium-90-labeled CHX-A''-C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice Cancer Res., September 1, 2004; 64(17): 6200 - 6206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Monte, R. Benetti, L. Collavin, L. Marchionni, G. Del Sal, and C. Schneider hGTSE-1 Expression Stimulates Cytoplasmic Localization of p53 J. Biol. Chem., March 19, 2004; 279(12): 11744 - 11752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-q. Yuan, R. I. Feldman, G. E. Sussman, D. Coppola, S. V. Nicosia, and J. Q. Cheng AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1: IMPLICATION OF AKT2 IN CHEMORESISTANCE J. Biol. Chem., June 20, 2003; 278(26): 23432 - 23440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vikhanskaya, M. D'Incalci, and M. Broggini p73 competes with p53 and attenuates its response in a human ovarian cancer cell line Nucleic Acids Res., January 15, 2000; 28(2): 513 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Passalaris, J. A. Benanti, L. Gewin, T. Kiyono, and D. A. Galloway The G2 Checkpoint Is Maintained by Redundant Pathways Mol. Cell. Biol., September 1, 1999; 19(9): 5872 - 5881. [Abstract] [Full Text] [PDF]
|
|